The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13)

Abstract Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) represents a rare entity that has been categorized as a disease‐defining recurring cytogenetic abnormality with adverse risk in the 2022 European LeukemiaNet classification. This rating was mainly based on a retrospective analysis comprising patients from several large clinical trials, which, however, included only 21 patients treated with allogeneic stem cell transplantation (alloSCT). Therefore, the European Society for Blood and Marrow Transplantation performed a registry study on a larger cohort to evaluate the role of alloSCT in t(8;16) AML. Sixty transplant recipients with t(8;16) AML were identified. Two‐year overall and leukemia‐free survival (OS/LFS) was 43/39%. Patients transplanted in first complete remission (CR1, n = 44) achieved a 2‐year OS/LFS of 48%/48%. Following alloSCT in CR1, the multivariable analysis identified a complex karyotype (CK) as a major risk factor for relapse (HR 4.17, p = .016), lower LFS (HR 3.38, p = .01), and lower OS (HR 3.08, p = .017). Two‐year OS/LFS of patients with CK was 19%/19%, in contrast to 67%/67% in patients with t(8;16) outside a CK. Other factors for inferior outcomes were older age and secondary AML. In summary, alloSCT could mitigate the adverse risk of patients with t(8;16) AML not harboring a CK, particularly when performed in CR1.

Authors

Institutions

Publication Details

Journal
American Journal of Hematology
Published
2024-11-18
DOI
https://doi.org/10.1002/ajh.27496
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13)

Myriam Labopin, Jordi Esteve, Gèrard Socié, Frédéric Baron et al.
American Journal of Hematology
Acute Myeloid Leukemia Research
article

The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13)

Myriam Labopin, Jordi Esteve, Gèrard Socié, Frédéric Baron, Peter A. von dem Borne, Mohamad Mohty, Matthias Eder, Ali Bazarbachi, Jurjen Versluis, Patrice Chevallier, Fabio Ciceri, Andreas Neubauer, Christoph Schmid, Arnon Nagler, Maria Pilar Gallego Hernanz, Gesine Bug, Ann-Kristin Schmaelter, Edouard Forcade
article en

Abstract

Abstract Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) represents a rare entity that has been categorized as a disease‐defining recurring cytogenetic abnormality with adverse risk in the 2022 European LeukemiaNet classification. This rating was mainly based on a retrospective analysis comprising patients from several large clinical trials, which, however, included only 21 patients treated with allogeneic stem cell transplantation (alloSCT). Therefore, the European Society for Blood and Marrow Transplantation performed a registry study on a larger cohort to evaluate the role of alloSCT in t(8;16) AML. Sixty transplant recipients with t(8;16) AML were identified. Two‐year overall and leukemia‐free survival (OS/LFS) was 43/39%. Patients transplanted in first complete remission (CR1, n = 44) achieved a 2‐year OS/LFS of 48%/48%. Following alloSCT in CR1, the multivariable analysis identified a complex karyotype (CK) as a major risk factor for relapse (HR 4.17, p = .016), lower LFS (HR 3.38, p = .01), and lower OS (HR 3.08, p = .017). Two‐year OS/LFS of patients with CK was 19%/19%, in contrast to 67%/67% in patients with t(8;16) outside a CK. Other factors for inferior outcomes were older age and secondary AML. In summary, alloSCT could mitigate the adverse risk of patients with t(8;16) AML not harboring a CK, particularly when performed in CR1.

American Journal of HematologyVol. 100(1)
Goethe University Frankfurt (DE), Leiden University (NL), University of Liège (BE), Philipps University of Marburg (DE), Tel Aviv University (IL), Sheba Medical Center (IL), Erasmus MC (NL), University Hospital Augsburg (DE), Centre Hospitalier Universitaire de Nantes (FR), Medizinische Hochschule Hannover (DE), Sorbonne Université (FR), Hôpital Saint-Antoine (FR), American University of Beirut Medical Center (LB), Centre Hospitalier Universitaire de Poitiers (FR), Hospital Clínic de Barcelona (ES), Hôpital Cardiologique du Haut-Lévêque (FR), University Hospital Frankfurt (DE), IRCCS Ospedale San Raffaele (IT), Hôpital Saint-Louis (FR), Erasmus MC Cancer Institute (NL), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), European Society for Blood and Marrow Transplantation (FR)
Good health and well-being
Openalex Percentile: Top 66%
Acute Myeloid Leukemia Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.